TIC10/ONC201-a potential therapeutic in glioblastoma

Affiliations

¹ Department of Neurological Surgery, Ulm University Medical Center, Ulm, Germany.
² Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.

Comment

Georg Karpel-Massler et al. Transl Cancer Res. 2017 Dec.

. 2017 Dec;6(Suppl 9):S1439-S1440.

doi: 10.21037/tcr.2017.10.51.

¹ Department of Neurological Surgery, Ulm University Medical Center, Ulm, Germany.
² Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.
Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. Arrillaga-Romany I, et al. Oncotarget. 2017 May 12;8(45):79298-79304. doi: 10.18632/oncotarget.17837. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108308 Free PMC article.

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96. - PubMed
1. Allen JE, Krigsfeld G, Mayes PA, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013;5:171ra17. - PMC - PubMed
1. Talekar MK, Allen J, Dicker D, et al. ONC201 induces cell death in pediatric non-Hodgkin’s lymphoma cells Cell Cycle 2015;14:2422–8. - PMC - PubMed
1. Prabhu VV, Allen JE, Dicker DT, et al. Small-Molecule ONC201/TIC10 Targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt/Foxo3a/TRAIL-dependent manner. Cancer Res 2015;75:1423–32. - PMC - PubMed
1. Zhang Q, Wang H, Ran L, et al. The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent. Biochem Biophys Res Commun 2016;476:260–6. - PubMed